SynthesisBMC cancer2018
Update on the types and usage of liquid biopsies in the clinical setting: a systematic review.
Synthesis in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Supernatant from endobronchial ultrasound-guided transbronchial needle aspiration samples for molecular profiling in NSCLC: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.Clinical epigenetics · 2023Pooled it
- Soft drugs: design principles and topical applications.Nature reviews. Drug discovery · 2026Review
- Clinical applications and future perspectives of circulating tumor cells in solid tumors.Discover oncology · 2026Review
- Assessment of 16S rRNA sequencing for analysis of circulating microbial DNA in colorectal cancer patients-proof of concept and early changes during experimental chemoimmunotherapy.Frontiers in microbiology · 2026Article
- Liquid Biopsy and Circulating Biomarkers in Head and Neck Cancer: Advancing Non-Invasive Detection and Tailored Management.Cancers · 2025Review
- Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma: A prospective multicenter cohort study.United European gastroenterology journal · 2025Article
- The times they are AI-changing: AI-powered advances in the application of extracellular vesicles to liquid biopsy in breast cancer.Extracellular vesicles and circulating nucleic acids · 2025Review
- Liquid biopsy in cancer management: Integrating diagnostics and clinical applications.Practical laboratory medicine · 2025Review
- MicroRNA-155 and its exosomal form: Small pieces in the gastrointestinal cancers puzzle.Cell biology and toxicology · 2024Review
- Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Evolving utility of exosomes in pancreatic cancer management.World journal of methodology · 2023Review
- All That Glitters in cfDNA Analysis Is Not Gold or Its Utility Is Completely Established Due to Graft Damage: A Critical Review in the Field of Transplantation.Diagnostics (Basel, Switzerland) · 2023Review
- Design of Polymeric Surfaces as Platforms for Streamlined Cancer Diagnostics in Liquid Biopsies.Biosensors · 2023Review
- Liquid biopsies: the future of cancer early detection.Journal of translational medicine · 2023Review
- Circulating Tumor Cells in Colorectal Cancer: Detection Systems and Clinical Utility.International journal of molecular sciences · 2022Review
- Article
- CirculatingInternational journal of molecular sciences · 2022Article
- Artificially Intelligent Nanoarray Detects Various Cancers by Liquid Biopsy of Volatile Markers.Advanced healthcare materials · 2022Article
- Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis systematic review aimed to gather evidence from research on the current state of liquid biopsy in medical practice, specifically focusing on mutation detection and monitoring.
methodsA systematic search was performed via Medline.
resultsThe results of this investigation indicate that liquid biopsy plays a critical role in the detection and management of tumors. This technique gives healthcare providers the ability to gather critical and reliable information that may potentially shape the diagnosis, treatment, and prognosis of a variety of cancers in the near future. This study further reveals that liquid biopsy has several potential shortcomings that may limit its application and use in the healthcare setting. Nevertheless, liquid biopsy remains a valuable tool that is gradually becoming a part of routine healthcare practice in oncology departments and hospitals worldwide.
conclusionsThe evidence described herein reveals the potential relevance of liquid biopsy as an important prognostic, diagnostic, and theranostic tool. This non-invasive procedure enables healthcare practitioners to detect and monitor genomic alterations and will likely replace tumor tissue biopsy as the standard method for detecting and monitoring mutations in the future. The information obtained herein can enable physicians to make informed decisions regarding current treatment options; however, liquid biopsy has not yet been incorporated into routine clinical diagnostics for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.